Drug therapy-related issues in patients who received bariatric surgery (part I)

Practical Gastroenterology

Volumn 34, Issue 7, 2010, Pages 26-32

  Chan, Lingtak Neander ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CARBAMAZEPINE; CEFPODOXIME PROXETIL; CEFUROXIME AXETIL; CHLOROQUINE; CLOFAZIMINE; DEXTROPROPOXYPHENE; GANCICLOVIR; GRISEOFULVIN; HYDRALAZINE; ITRACONAZOLE; KETOCONAZOLE; LARIUM; LITHIUM; MEFLOQUINE; METHYLPHENIDATE; NELFINAVIR; PROPRANOLOL; RITONAVIR; SAQUINAVIR; SELEGILINE; SPIRONOLACTONE; SPRANOX; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; BARIATRIC SURGERY; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG THERAPY; DRUG TRANSFORMATION; DRUG TRANSPORT; FOOD DRUG INTERACTION; GASTRIC BANDING; GASTROINTESTINAL ABSORPTION; HUMAN; PATIENT CARE; ROUX Y ANASTOMOSIS;

EID: 78149235739     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sjöström L. Surgical intervention as strategy for treatment of obesity. Endocrine 2000;13(2):213-30.
2. Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: an 18-year report from the International Bariatric Surgery Reg- istry. Am J Surg. 2006;192(5):657-62.
3. Picot, J, Jones, J, Colquitt, JL, et al The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13(41):1-190, 215-357, iii-iv.
4. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 dia- betes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-256.
5. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg. 2009;19(12):1605-11.
6. Abeles D, Shikora SA. Bariatric surgery: current concepts and future directions. Aesthet Surg J. 2008 Jan-Feb;28(1):79-84.
7. Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinol Metab Clin North Am. 2008;37(4):943-64.
8. Ward M, Prachand V. Surgical treatment of obesity. Gastrointest Endosc. 2009;70(5):985-90.
9. Sjöström L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008;32 Suppl 7:S93-7.
10. Sjöström L, Narbro K, Sjöström CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-52.
11. Karlsson J, Taft C, Rydén A, et al. Ten-year trends in health related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007;31(8):1248-61.
12. Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2008;4(3 Suppl):S47-55.
13. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology. 2007;132(6):2253-71.
14. Jan JC, Hong D, Bardaro SJ, et al. Comparative study between laparoscopic adjustable gastric banding and laparoscopic gastric bypass: single-institution, 5-year experience in bariatric surgery, Surg Obes Relat Dis 2007;3:42-51.
15. O'Brien PE and Dixon JB, Lap-Band: Outcomes and results, J Laparoendosc Adv Surg Tech 2003 13:265-270.
16. Melia CD, Davis SS. Review article: mechanisms of drug release from tablets and capsules. I: Disintegration. Aliment Pharmacol Ther. 1989;3(3):223-32.
17. Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-40.
18. Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-21. Erratum in: Aliment Pharmacol Ther 1993;7(5):587.
19. Freeman J, Heshmati A, Holland D, et al. Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation. J Antimicrob Chemother. 2007;60(4):908-9.
20. Johnson MD, Hamilton CD, Drew RH, et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51(2):453-7.
21. Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci. 2008 Mar;97(3):1109-34.
22. Thwaites DT, Anderson CM. H+coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007;92(4):603-19.
23. Ogihara T, Kano T, Wagatsuma T, et al. Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos. 2009;37(8):1676-81.
24. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26(9): 2039-54.
25. Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008;4(7):923-39.
26. Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35(8):1333-40.
27. Chan, L-N, Lin YS, Oelschlager BK, et al. Effect of Proximal Roux-en-Y Gastric Bypass on Oral Bioavailability of P-glycoprotein Substrates [Abstract]. American College of Clinical Pharmacy Annual Meeting 2009, Anaheim, California
28. Ritter JK. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol. 2007;3(1):93-107.
29. Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol. 2004;18(6):621-6.